nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyl aminolevulinate—Macular oedema—Zidovudine—acquired immunodeficiency syndrome	0.0349	0.0405	CcSEcCtD
Methyl aminolevulinate—Sensitisation—Abacavir—acquired immunodeficiency syndrome	0.027	0.0314	CcSEcCtD
Methyl aminolevulinate—Skin infection—Indinavir—acquired immunodeficiency syndrome	0.0262	0.0305	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Regulation of actin dynamics for phagocytic cup formation—ACTG1—acquired immunodeficiency syndrome	0.0254	0.183	CbGpPWpGaD
Methyl aminolevulinate—Sensitisation—Zidovudine—acquired immunodeficiency syndrome	0.0238	0.0277	CcSEcCtD
Methyl aminolevulinate—Skin infection—Lamivudine—acquired immunodeficiency syndrome	0.0201	0.0234	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—ACTG1—acquired immunodeficiency syndrome	0.0192	0.138	CbGpPWpGaD
Methyl aminolevulinate—Sensitisation—Lamivudine—acquired immunodeficiency syndrome	0.017	0.0198	CcSEcCtD
Methyl aminolevulinate—Blister—Nevirapine—acquired immunodeficiency syndrome	0.0141	0.0164	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Indinavir—acquired immunodeficiency syndrome	0.0133	0.0155	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Efavirenz—acquired immunodeficiency syndrome	0.0126	0.0146	CcSEcCtD
Methyl aminolevulinate—Ulcer—Nevirapine—acquired immunodeficiency syndrome	0.0107	0.0125	CcSEcCtD
Methyl aminolevulinate—Blister—Efavirenz—acquired immunodeficiency syndrome	0.0104	0.0121	CcSEcCtD
Methyl aminolevulinate—Blister—Delavirdine—acquired immunodeficiency syndrome	0.00993	0.0115	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Nevirapine—acquired immunodeficiency syndrome	0.00969	0.0113	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—HLA-B—acquired immunodeficiency syndrome	0.00951	0.0684	CbGpPWpGaD
Methyl aminolevulinate—Rash pustular—Efavirenz—acquired immunodeficiency syndrome	0.00938	0.0109	CcSEcCtD
Methyl aminolevulinate—Rash pustular—Delavirdine—acquired immunodeficiency syndrome	0.00898	0.0104	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—HLA-B—acquired immunodeficiency syndrome	0.00845	0.0608	CbGpPWpGaD
Methyl aminolevulinate—Rash pustular—Ritonavir—acquired immunodeficiency syndrome	0.0083	0.00964	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Saquinavir—acquired immunodeficiency syndrome	0.00818	0.00951	CcSEcCtD
Methyl aminolevulinate—Ulcer—Efavirenz—acquired immunodeficiency syndrome	0.00791	0.00919	CcSEcCtD
Methyl aminolevulinate—Dermatitis contact—Indinavir—acquired immunodeficiency syndrome	0.00783	0.00909	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Nevirapine—acquired immunodeficiency syndrome	0.00771	0.00895	CcSEcCtD
Methyl aminolevulinate—Ulcer—Delavirdine—acquired immunodeficiency syndrome	0.00757	0.00879	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Nelfinavir—acquired immunodeficiency syndrome	0.00746	0.00867	CcSEcCtD
Methyl aminolevulinate—Eye irritation—Saquinavir—acquired immunodeficiency syndrome	0.00746	0.00867	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Efavirenz—acquired immunodeficiency syndrome	0.00714	0.0083	CcSEcCtD
Methyl aminolevulinate—Face oedema—Nevirapine—acquired immunodeficiency syndrome	0.00711	0.00826	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Delavirdine—acquired immunodeficiency syndrome	0.00684	0.00794	CcSEcCtD
Methyl aminolevulinate—Ulcer—Saquinavir—acquired immunodeficiency syndrome	0.00674	0.00782	CcSEcCtD
Methyl aminolevulinate—Dermatitis contact—Ritonavir—acquired immunodeficiency syndrome	0.00654	0.0076	CcSEcCtD
Methyl aminolevulinate—Swelling—Indinavir—acquired immunodeficiency syndrome	0.00652	0.00757	CcSEcCtD
Methyl aminolevulinate—Eye pain—Indinavir—acquired immunodeficiency syndrome	0.00637	0.0074	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—IFNA1—acquired immunodeficiency syndrome	0.00617	0.0444	CbGpPWpGaD
Methyl aminolevulinate—Eczema—Efavirenz—acquired immunodeficiency syndrome	0.00604	0.00702	CcSEcCtD
Methyl aminolevulinate—Swelling—Delavirdine—acquired immunodeficiency syndrome	0.00589	0.00684	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—IFNG—acquired immunodeficiency syndrome	0.00588	0.0423	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis bullous—Efavirenz—acquired immunodeficiency syndrome	0.00568	0.0066	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Delavirdine—acquired immunodeficiency syndrome	0.00544	0.00632	CcSEcCtD
Methyl aminolevulinate—Eczema—Ritonavir—acquired immunodeficiency syndrome	0.00535	0.00621	CcSEcCtD
Methyl aminolevulinate—Eye pain—Ritonavir—acquired immunodeficiency syndrome	0.00532	0.00618	CcSEcCtD
Methyl aminolevulinate—Eczema—Saquinavir—acquired immunodeficiency syndrome	0.00515	0.00598	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Ritonavir—acquired immunodeficiency syndrome	0.00503	0.00584	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Saquinavir—acquired immunodeficiency syndrome	0.00484	0.00562	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—HLA-B—acquired immunodeficiency syndrome	0.00464	0.0334	CbGpPWpGaD
Methyl aminolevulinate—Face oedema—Ritonavir—acquired immunodeficiency syndrome	0.00464	0.00539	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Nelfinavir—acquired immunodeficiency syndrome	0.00461	0.00536	CcSEcCtD
Methyl aminolevulinate—Discomfort—Amprenavir—acquired immunodeficiency syndrome	0.00455	0.00529	CcSEcCtD
Methyl aminolevulinate—Erythema—Nevirapine—acquired immunodeficiency syndrome	0.00444	0.00515	CcSEcCtD
Methyl aminolevulinate—Erythema—Nelfinavir—acquired immunodeficiency syndrome	0.0043	0.00499	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Efavirenz—acquired immunodeficiency syndrome	0.00429	0.00498	CcSEcCtD
Methyl aminolevulinate—Discomfort—Didanosine—acquired immunodeficiency syndrome	0.00415	0.00482	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IFNA1—acquired immunodeficiency syndrome	0.00412	0.0296	CbGpPWpGaD
Methyl aminolevulinate—Infection—Didanosine—acquired immunodeficiency syndrome	0.004	0.00465	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	0.00398	0.0287	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Amprenavir—acquired immunodeficiency syndrome	0.00397	0.00461	CcSEcCtD
Methyl aminolevulinate—Fatigue—Amprenavir—acquired immunodeficiency syndrome	0.00381	0.00442	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Ritonavir—acquired immunodeficiency syndrome	0.00379	0.0044	CcSEcCtD
Methyl aminolevulinate—Discomfort—Nevirapine—acquired immunodeficiency syndrome	0.00373	0.00433	CcSEcCtD
Methyl aminolevulinate—Erythema—Zidovudine—acquired immunodeficiency syndrome	0.00372	0.00432	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Saquinavir—acquired immunodeficiency syndrome	0.00365	0.00424	CcSEcCtD
Methyl aminolevulinate—Oedema—Nevirapine—acquired immunodeficiency syndrome	0.00362	0.0042	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Didanosine—acquired immunodeficiency syndrome	0.00362	0.0042	CcSEcCtD
Methyl aminolevulinate—Discomfort—Nelfinavir—acquired immunodeficiency syndrome	0.00361	0.0042	CcSEcCtD
Methyl aminolevulinate—Discomfort—Abacavir—acquired immunodeficiency syndrome	0.00355	0.00412	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Efavirenz—acquired immunodeficiency syndrome	0.00351	0.00408	CcSEcCtD
Methyl aminolevulinate—Oedema—Nelfinavir—acquired immunodeficiency syndrome	0.00351	0.00407	CcSEcCtD
Methyl aminolevulinate—Oedema—Abacavir—acquired immunodeficiency syndrome	0.00344	0.004	CcSEcCtD
Methyl aminolevulinate—Pain—Didanosine—acquired immunodeficiency syndrome	0.00344	0.004	CcSEcCtD
Methyl aminolevulinate—Infection—Abacavir—acquired immunodeficiency syndrome	0.00342	0.00397	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—HLA-B—acquired immunodeficiency syndrome	0.00337	0.0243	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—MBL2—acquired immunodeficiency syndrome	0.00327	0.0235	CbGpPWpGaD
Methyl aminolevulinate—Erythema—Efavirenz—acquired immunodeficiency syndrome	0.00327	0.0038	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Nevirapine—acquired immunodeficiency syndrome	0.00325	0.00378	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—CSF2—acquired immunodeficiency syndrome	0.00322	0.0232	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.00317	0.00368	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Nelfinavir—acquired immunodeficiency syndrome	0.00315	0.00366	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Stavudine—acquired immunodeficiency syndrome	0.00314	0.00365	CcSEcCtD
Methyl aminolevulinate—Discomfort—Zidovudine—acquired immunodeficiency syndrome	0.00313	0.00364	CcSEcCtD
Methyl aminolevulinate—Erythema—Delavirdine—acquired immunodeficiency syndrome	0.00313	0.00363	CcSEcCtD
Methyl aminolevulinate—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.00312	0.00363	CcSEcCtD
Methyl aminolevulinate—Fatigue—Nevirapine—acquired immunodeficiency syndrome	0.00312	0.00363	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Ritonavir—acquired immunodeficiency syndrome	0.00311	0.00361	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—HLA-B—acquired immunodeficiency syndrome	0.0031	0.0223	CbGpPWpGaD
Methyl aminolevulinate—Pain—Nevirapine—acquired immunodeficiency syndrome	0.0031	0.0036	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Abacavir—acquired immunodeficiency syndrome	0.00309	0.00359	CcSEcCtD
Methyl aminolevulinate—Oedema—Zidovudine—acquired immunodeficiency syndrome	0.00304	0.00353	CcSEcCtD
Methyl aminolevulinate—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.00301	0.0035	CcSEcCtD
Methyl aminolevulinate—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.003	0.00348	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Saquinavir—acquired immunodeficiency syndrome	0.00299	0.00347	CcSEcCtD
Methyl aminolevulinate—Pain—Stavudine—acquired immunodeficiency syndrome	0.00299	0.00347	CcSEcCtD
Methyl aminolevulinate—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.00297	0.00345	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.00297	0.00345	CcSEcCtD
Methyl aminolevulinate—Pain—Abacavir—acquired immunodeficiency syndrome	0.00294	0.00342	CcSEcCtD
Methyl aminolevulinate—Discomfort—Indinavir—acquired immunodeficiency syndrome	0.00291	0.00338	CcSEcCtD
Methyl aminolevulinate—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.00289	0.00335	CcSEcCtD
Methyl aminolevulinate—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.00288	0.00334	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—IFNG—acquired immunodeficiency syndrome	0.00287	0.0207	CbGpPWpGaD
Methyl aminolevulinate—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.00285	0.00331	CcSEcCtD
Methyl aminolevulinate—Oedema—Indinavir—acquired immunodeficiency syndrome	0.00283	0.00328	CcSEcCtD
Methyl aminolevulinate—Erythema—Saquinavir—acquired immunodeficiency syndrome	0.00279	0.00324	CcSEcCtD
Methyl aminolevulinate—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.00279	0.00323	CcSEcCtD
Methyl aminolevulinate—Rash—Amprenavir—acquired immunodeficiency syndrome	0.00278	0.00323	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.00278	0.00323	CcSEcCtD
Methyl aminolevulinate—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.00278	0.00323	CcSEcCtD
Methyl aminolevulinate—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00277	0.00321	CcSEcCtD
Methyl aminolevulinate—Discomfort—Efavirenz—acquired immunodeficiency syndrome	0.00275	0.0032	CcSEcCtD
Methyl aminolevulinate—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.00274	0.00318	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	0.00273	0.00317	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.00267	0.0031	CcSEcCtD
Methyl aminolevulinate—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.00266	0.00309	CcSEcCtD
Methyl aminolevulinate—Discomfort—Delavirdine—acquired immunodeficiency syndrome	0.00263	0.00306	CcSEcCtD
Methyl aminolevulinate—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00262	0.00305	CcSEcCtD
Methyl aminolevulinate—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.00262	0.00304	CcSEcCtD
Methyl aminolevulinate—Pain—Zidovudine—acquired immunodeficiency syndrome	0.0026	0.00302	CcSEcCtD
Methyl aminolevulinate—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.0026	0.00302	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.00258	0.003	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.00258	0.00299	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CCR2—acquired immunodeficiency syndrome	0.00257	0.0185	CbGpPWpGaD
Methyl aminolevulinate—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.00256	0.00297	CcSEcCtD
Methyl aminolevulinate—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.00255	0.00297	CcSEcCtD
Methyl aminolevulinate—Rash—Didanosine—acquired immunodeficiency syndrome	0.00254	0.00295	CcSEcCtD
Methyl aminolevulinate—Infection—Delavirdine—acquired immunodeficiency syndrome	0.00254	0.00295	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.00254	0.00295	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.00254	0.00295	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.00254	0.00295	CcSEcCtD
Methyl aminolevulinate—Headache—Didanosine—acquired immunodeficiency syndrome	0.00252	0.00293	CcSEcCtD
Methyl aminolevulinate—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.00252	0.00292	CcSEcCtD
Methyl aminolevulinate—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.00251	0.00291	CcSEcCtD
Methyl aminolevulinate—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.00248	0.00288	CcSEcCtD
Methyl aminolevulinate—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.00247	0.00287	CcSEcCtD
Methyl aminolevulinate—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.00247	0.00287	CcSEcCtD
Methyl aminolevulinate—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.00244	0.00283	CcSEcCtD
Methyl aminolevulinate—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.00244	0.00283	CcSEcCtD
Methyl aminolevulinate—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.00243	0.00283	CcSEcCtD
Methyl aminolevulinate—Pain—Indinavir—acquired immunodeficiency syndrome	0.00242	0.00281	CcSEcCtD
Methyl aminolevulinate—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.00241	0.0028	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.0024	0.00278	CcSEcCtD
Methyl aminolevulinate—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00239	0.00278	CcSEcCtD
Methyl aminolevulinate—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.00236	0.00274	CcSEcCtD
Methyl aminolevulinate—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.00234	0.00272	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—ACTG1—acquired immunodeficiency syndrome	0.00232	0.0167	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00232	0.00269	CcSEcCtD
Methyl aminolevulinate—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00231	0.00268	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	0.00231	0.0166	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.0023	0.00267	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.00229	0.00266	CcSEcCtD
Methyl aminolevulinate—Pain—Efavirenz—acquired immunodeficiency syndrome	0.00228	0.00265	CcSEcCtD
Methyl aminolevulinate—Rash—Nevirapine—acquired immunodeficiency syndrome	0.00228	0.00265	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.00228	0.00265	CcSEcCtD
Methyl aminolevulinate—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00228	0.00264	CcSEcCtD
Methyl aminolevulinate—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.00227	0.00264	CcSEcCtD
Methyl aminolevulinate—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00227	0.00263	CcSEcCtD
Methyl aminolevulinate—Infection—Saquinavir—acquired immunodeficiency syndrome	0.00226	0.00262	CcSEcCtD
Methyl aminolevulinate—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.00224	0.00261	CcSEcCtD
Methyl aminolevulinate—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.00224	0.0026	CcSEcCtD
Methyl aminolevulinate—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.00221	0.00257	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.00221	0.00257	CcSEcCtD
Methyl aminolevulinate—Rash—Stavudine—acquired immunodeficiency syndrome	0.0022	0.00256	CcSEcCtD
Methyl aminolevulinate—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.0022	0.00256	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.0022	0.00256	CcSEcCtD
Methyl aminolevulinate—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.0022	0.00255	CcSEcCtD
Methyl aminolevulinate—Headache—Stavudine—acquired immunodeficiency syndrome	0.00219	0.00254	CcSEcCtD
Methyl aminolevulinate—Pain—Delavirdine—acquired immunodeficiency syndrome	0.00218	0.00254	CcSEcCtD
Methyl aminolevulinate—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.00218	0.00253	CcSEcCtD
Methyl aminolevulinate—Rash—Abacavir—acquired immunodeficiency syndrome	0.00217	0.00252	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.00217	0.00252	CcSEcCtD
Methyl aminolevulinate—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.00217	0.00252	CcSEcCtD
Methyl aminolevulinate—Headache—Abacavir—acquired immunodeficiency syndrome	0.00216	0.00251	CcSEcCtD
Methyl aminolevulinate—Infection—Lamivudine—acquired immunodeficiency syndrome	0.00215	0.0025	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	0.00215	0.0155	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00215	0.0025	CcSEcCtD
Methyl aminolevulinate—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.00215	0.0025	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.00212	0.00246	CcSEcCtD
Methyl aminolevulinate—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.00212	0.00246	CcSEcCtD
Methyl aminolevulinate—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.00208	0.00242	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.00208	0.00242	CcSEcCtD
Methyl aminolevulinate—Nausea—Stavudine—acquired immunodeficiency syndrome	0.00208	0.00241	CcSEcCtD
Methyl aminolevulinate—Nausea—Abacavir—acquired immunodeficiency syndrome	0.00205	0.00238	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.00204	0.00237	CcSEcCtD
Methyl aminolevulinate—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.00204	0.00237	CcSEcCtD
Methyl aminolevulinate—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.00203	0.00236	CcSEcCtD
Methyl aminolevulinate—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.00203	0.00235	CcSEcCtD
Methyl aminolevulinate—Pain—Ritonavir—acquired immunodeficiency syndrome	0.00202	0.00235	CcSEcCtD
Methyl aminolevulinate—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.00201	0.00233	CcSEcCtD
Methyl aminolevulinate—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.002	0.00232	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.00197	0.00228	CcSEcCtD
Methyl aminolevulinate—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.00196	0.00228	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.00195	0.00226	CcSEcCtD
Methyl aminolevulinate—Pain—Saquinavir—acquired immunodeficiency syndrome	0.00194	0.00226	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IFNG—acquired immunodeficiency syndrome	0.00192	0.0138	CbGpPWpGaD
Methyl aminolevulinate—Rash—Zidovudine—acquired immunodeficiency syndrome	0.00192	0.00222	CcSEcCtD
Methyl aminolevulinate—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.00192	0.00222	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.00191	0.00222	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—MBL2—acquired immunodeficiency syndrome	0.00191	0.0137	CbGpPWpGaD
Methyl aminolevulinate—Headache—Zidovudine—acquired immunodeficiency syndrome	0.0019	0.00221	CcSEcCtD
Methyl aminolevulinate—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.00189	0.00219	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.00188	0.00219	CcSEcCtD
Methyl aminolevulinate—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.00188	0.00218	CcSEcCtD
Methyl aminolevulinate—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.00187	0.00217	CcSEcCtD
Methyl aminolevulinate—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00187	0.00217	CcSEcCtD
Methyl aminolevulinate—Pain—Lamivudine—acquired immunodeficiency syndrome	0.00185	0.00215	CcSEcCtD
Methyl aminolevulinate—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.00183	0.00213	CcSEcCtD
Methyl aminolevulinate—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.00181	0.0021	CcSEcCtD
Methyl aminolevulinate—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.00181	0.0021	CcSEcCtD
Methyl aminolevulinate—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.0018	0.0021	CcSEcCtD
Methyl aminolevulinate—Rash—Indinavir—acquired immunodeficiency syndrome	0.00178	0.00207	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.00178	0.00207	CcSEcCtD
Methyl aminolevulinate—Headache—Indinavir—acquired immunodeficiency syndrome	0.00177	0.00206	CcSEcCtD
Methyl aminolevulinate—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00177	0.00205	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	0.00176	0.0126	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.00174	0.00202	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	0.00174	0.0125	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	0.00174	0.0125	CbGpPWpGaD
Methyl aminolevulinate—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.00172	0.002	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL2—acquired immunodeficiency syndrome	0.0017	0.0123	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.00169	0.00197	CcSEcCtD
Methyl aminolevulinate—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.00169	0.00196	CcSEcCtD
Methyl aminolevulinate—Rash—Efavirenz—acquired immunodeficiency syndrome	0.00168	0.00195	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.00168	0.00195	CcSEcCtD
Methyl aminolevulinate—Nausea—Indinavir—acquired immunodeficiency syndrome	0.00168	0.00195	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.00167	0.00195	CcSEcCtD
Methyl aminolevulinate—Headache—Efavirenz—acquired immunodeficiency syndrome	0.00167	0.00194	CcSEcCtD
Methyl aminolevulinate—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.00167	0.00194	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	0.00167	0.012	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.00163	0.00189	CcSEcCtD
Methyl aminolevulinate—Rash—Delavirdine—acquired immunodeficiency syndrome	0.00161	0.00187	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.00161	0.00187	CcSEcCtD
Methyl aminolevulinate—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.00161	0.00187	CcSEcCtD
Methyl aminolevulinate—Headache—Delavirdine—acquired immunodeficiency syndrome	0.0016	0.00186	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.0016	0.00186	CcSEcCtD
Methyl aminolevulinate—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.00159	0.00184	CcSEcCtD
Methyl aminolevulinate—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.00156	0.00181	CcSEcCtD
Methyl aminolevulinate—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.00156	0.00181	CcSEcCtD
Methyl aminolevulinate—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.00153	0.00178	CcSEcCtD
Methyl aminolevulinate—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00152	0.00176	CcSEcCtD
Methyl aminolevulinate—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.0015	0.00175	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CCR2—acquired immunodeficiency syndrome	0.00149	0.0108	CbGpPWpGaD
Methyl aminolevulinate—Rash—Ritonavir—acquired immunodeficiency syndrome	0.00149	0.00173	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.00149	0.00173	CcSEcCtD
Methyl aminolevulinate—Headache—Ritonavir—acquired immunodeficiency syndrome	0.00148	0.00172	CcSEcCtD
Methyl aminolevulinate—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00143	0.00167	CcSEcCtD
Methyl aminolevulinate—Rash—Saquinavir—acquired immunodeficiency syndrome	0.00143	0.00166	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.00143	0.00166	CcSEcCtD
Methyl aminolevulinate—Headache—Saquinavir—acquired immunodeficiency syndrome	0.00142	0.00165	CcSEcCtD
Methyl aminolevulinate—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.0014	0.00163	CcSEcCtD
Methyl aminolevulinate—Rash—Lamivudine—acquired immunodeficiency syndrome	0.00137	0.00159	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.00137	0.00159	CcSEcCtD
Methyl aminolevulinate—Headache—Lamivudine—acquired immunodeficiency syndrome	0.00136	0.00158	CcSEcCtD
Methyl aminolevulinate—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.00135	0.00157	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—IFNA1—acquired immunodeficiency syndrome	0.00135	0.00968	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CD79A—acquired immunodeficiency syndrome	0.00131	0.0094	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.00129	0.0015	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CD40LG—acquired immunodeficiency syndrome	0.00106	0.00766	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CSF2—acquired immunodeficiency syndrome	0.00105	0.00758	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CD8A—acquired immunodeficiency syndrome	0.00105	0.00758	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CD4—acquired immunodeficiency syndrome	0.00104	0.00747	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—HLA-B—acquired immunodeficiency syndrome	0.00101	0.00729	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	0.001	0.00721	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	0.000997	0.00718	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IFNG—acquired immunodeficiency syndrome	0.000626	0.00451	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CD4—acquired immunodeficiency syndrome	0.000605	0.00435	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—IL6—acquired immunodeficiency syndrome	0.000562	0.00404	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL2—acquired immunodeficiency syndrome	0.000556	0.004	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL6—acquired immunodeficiency syndrome	0.000327	0.00235	CbGpPWpGaD
